MARKET

CELC

CELC

Celcuity Inc
NASDAQ
126.07
+5.98
+4.98%
After Hours: 127.00 +0.93 +0.74% 19:57 04/21 EDT
OPEN
119.64
PREV CLOSE
120.09
HIGH
127.18
LOW
117.56
VOLUME
751.65K
TURNOVER
--
52 WEEK HIGH
127.34
52 WEEK LOW
9.51
MARKET CAP
6.09B
P/E (TTM)
-33.2955
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CELC last week (0413-0417)?
Weekly Report · 1d ago
Weekly Report: what happened at CELC last week (0406-0410)?
Weekly Report · 04/13 09:05
Weekly Report: what happened at CELC last week (0330-0403)?
Weekly Report · 04/06 09:05
Celcuity director Richard E. Buller disposes CELC shares worth 0.3 million
Reuters · 04/02 20:07
Weekly Report: what happened at CELC last week (0323-0327)?
Weekly Report · 03/30 09:05
H.C. Wainwright Sticks to Their Hold Rating for Celcuity (CELC)
TipRanks · 03/27 10:57
Celcuity’s Earnings Call: Big Data, Bigger Ambitions
TipRanks · 03/27 00:26
Celcuity Buy Rating Backed by Strong Gedatolisib Data, Upcoming VIKTORIA-1 Catalyst, and Favorable Risk-Reward
TipRanks · 03/26 17:35
More
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.

Webull offers Celcuity Inc stock information, including NASDAQ: CELC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CELC stock methods without spending real money on the virtual paper trading platform.